Back to News
Market Impact: 0.32

Rothschild Redburn upgrades Rollins stock on valuation, raises PT to $66

ROL
Analyst InsightsCorporate EarningsCompany FundamentalsCorporate Guidance & OutlookCapital Returns (Dividends / Buybacks)
Rothschild Redburn upgrades Rollins stock on valuation, raises PT to $66

Rothschild Redburn upgraded Rollins to Buy from Neutral and raised its price target to $66 from $51.50, implying 16% upside. The firm cited resilient recurring contract revenue of about 7%, 52.6% gross margin, 11% trailing 12-month revenue growth, and expected 12% EPS and free cash flow compound growth. Rollins also recently reported Q1 2026 EPS of $0.24 versus $0.23 expected and revenue of $906.42 million versus $894.58 million expected.

Analysis

The clean read-through is that this is not a “growth at any price” call; it is a quality-duration re-rating on a defensive compounder. If management can keep mid-single-digit recurring growth intact while maintaining high incremental margins, the market can justify a premium multiple even without a step-change in top-line acceleration. The key second-order effect is on capital allocation: a business with stable cash conversion and modest reinvestment needs can compound via buybacks, which tends to compress volatility and attract yield-oriented institutional flows over the next 6-12 months. The market is likely underestimating how much of the recent valuation reset was tied to fear of normalization in one-time work rather than a deterioration in the core installed base. That matters because competitors that depend more heavily on discretionary or project-driven revenue will screen cheaper, but they are more exposed if macro weakens or if pricing discipline holds. In other words, the relative winner is the name with the most predictable renewal engine, while smaller fragmented operators may see multiple pressure if investors re-anchor on quality over headline growth. The main risk is not demand collapse; it is multiple compression if rates stay high and the market rotates away from defensive compounders before the next clean earnings beat. Near term, the stock likely trades on guidance credibility over the next 1-2 quarters; over 12 months, the path depends on whether the company proves that organic growth can re-accelerate without sacrificing margin. Contrarian take: the market may still be too focused on the slowdown in recent quarters and not enough on the asymmetry that a stable recurring base plus buybacks can create a 15-20% total return profile even with only modest operating improvement.